Researchers have analysed the efficacy of the meningococcal serogroup B vaccine (4CMenB, Bexsero) in more than 1,500 children under five years of age in Spain. The research, published in the New England Journal of Medicine, shows that full vaccination was effective in preventing invasive meningococcal disease of both serogroup B and other serogroups in this child population. The vaccine, which had been sold privately in Spain since 2015, had already been included by several autonomous communities in their vaccination schedules. Last December, the Interterritorial Council of the National Health System (CISNS) approved its inclusion in the vaccination schedule for the whole of Spain.
When science hits the headlines, we seek the views of expert sources who assess the news rigorously and quickly, according to the available evidence.